goserelin
goserelin: 20 clinical trials tracked.
goserelin evidence translation
What we can confirm
20 tracked trials
What it means
What to watch
Prepared research question
What is verified about goserelin, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 8 study sponsors
Related indications
Clinical Trials (20)showing 10 most recent
preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women With Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Primary endpoint: Change from Baseline in Antigen Kiel (Ki-67) Expression
Phase 2 Randomized Trial to Examine Ovarian Function Suppression for Breast Cancer (OFS)
Primary endpoint: Proportion of participants with ultrasensitive estradiol concentration > 10 pg/ml
A Phase 1, Open Label, Randomized, 2-sequence, 2-period, Cross-over, Single Center Study to Assess the Bioequivalence of Follitropin Alfa Solution for Injection in Prefilled Pen (Test) and Follitropin Alfa Powder and Diluent for Solution for Injection in Vial (Reference) in Healthy Downregulated Male Participants
Primary endpoint: Baseline Adjusted Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Sampling Time After Administration (AUC0-t, adj) of Follitropin Alfa
SELECT: A Phase II Adjuvant Trial Evaluating the Impact of Omitting Chemotherapy Based on Patient's Selection for Moderate to High-Anatomical Risk, Low-Genomic Risk, ER-Positive, HER2- Negative Breast Cancer With a Combination Regimen of Ribociclib and Optimized Endocrine Therapy
Primary endpoint: Discontinuation rate of ribociclib in patients with resected moderate to high-anatomical risk, low-genomic risk, ER-positive, HER2-negative breast cancer
MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer
Primary endpoint: Modified radiographic progression-free survival (mrPFS) (Groups A & B)
A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Primary endpoint: Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years
A Phase 2 Trial of (Z)-Endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women With ER+, HER2-, Breast Cancer
Primary endpoint: PK Cohort - (Z)-endoxifen steady-state plasma concentrations
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Primary endpoint: Body Mass Index (BMI)
A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study
Primary endpoint: Percentage of participants with treatment-emergent adverse events (AES)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
Primary endpoint: Distant metastasis (DM) (De-intensification study)